Myovant Sciences Ltd (MYOV)

followers · Follow

Sector:

HEALTH CARE

Industry:

BIOTECHNOLOGY & LIFE SCIENCES

SIC:

PHARMACEUTICAL PREPARATIONS

CEO:

David C. Marek

Employees:

580

SUITE 1, 3RD FLOOR, 11-12 ST. JAMES SQUARE, LONDON, X0, SW1Y 4LB

44 207-400-3351

myovant.com

Myovant Sciences Ltd. focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction.

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

Myovant Sciences Ltd YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available